Antibacterial prophylaxis in chronic granulomatous disease. A case report
- PMID: 6607239
Antibacterial prophylaxis in chronic granulomatous disease. A case report
Abstract
The value of long-term prophylactic treatment of chronic granulomatous disease (CGD) in childhood cannot be established with certainty, as controlled studies are not available. We describe a boy, presently 15 years old, who suffered from CGD since early infancy. By the clinical, laboratory and genetic features, this case appeared to be a new variant of CGD, combining elements of the "childhood" type with others that characterize the "adult" type of the syndrome. For years, the patient had been almost continuously ill and needed frequent and prolonged hospitalizations because of severe bacterial infections. At age 13 years, long-term prophylactic treatment with trimethoprim-sulfamethoxazole (TMP-SMX) was instituted. With this regimen, the patient was maintained practically infection-free, relapsing only in those instances when he neglected to comply with the prophylactic regimen for 1 to 2 weeks. Thus, the patient served as his own control in demonstrating the efficacy of antimicrobial prophylaxis in CGD. The rationale for employing TMP-SMX for the prophylactic regimen is discussed.
Similar articles
-
Chronic granulomatous disease: effect of sulfamethoxazole/trimethoprim on neutrophil microbicidal function.Helv Paediatr Acta. 1981;36(6):579-88. Helv Paediatr Acta. 1981. PMID: 7333866
-
Clinical features and current management of chronic granulomatous disease.Hematol Oncol Clin North Am. 1988 Jun;2(2):253-66. Hematol Oncol Clin North Am. 1988. PMID: 2839458
-
Surgery and granulocyte transfusions for life-threatening infections in chronic granulomatous disease.Helv Paediatr Acta. 1985 Sep;40(4):277-84. Helv Paediatr Acta. 1985. PMID: 3878346
-
[Antibiotherapy in chronic familial granulomatosis].Pathol Biol (Paris). 1990 Apr;38(4):294-7. Pathol Biol (Paris). 1990. PMID: 2198524 Review. French.
-
Trimethoprim-sulfamethoxazole as a viable treatment option for infections caused by methicillin-resistant Staphylococcus aureus.Pharmacotherapy. 2005 Feb;25(2):253-64. doi: 10.1592/phco.25.2.253.56956. Pharmacotherapy. 2005. PMID: 15767239 Review.